Bhatia, Aarti http://orcid.org/0000-0002-0491-4454
Burtness, Barbara
Article History
Accepted: 3 January 2023
First Online: 16 January 2023
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Aarti Bhatia: Research funding from Boehringer-Ingelheim and Genentech. Consultant fees from Regeneron, Sanofi-Genzyme, and Merck. Barbara Burtness: Consulting for Cue Biopharma, Debio, Genentech, IO Biotech, Kura, ALX Oncology, Merck, Merck KgA, Vaccinex, Exelexis, Glaxo Smith Kline. Research funding from Bristol Myers Squibb, Cue BioPharma, Exelexis, Merck, Merck KgA, RBN.
: Not applicable.
: Not applicable.
: Both authors AB and BB consent to the publication of this manuscript.
: Not applicable.
: Not applicable.
: Both authors AB and BB contributed equally to the preparation of this manuscript.